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PD-1 and PD-L1 inhibitors: a single center Medication Assistance Program (MAP) experience
Sarah Tu, PharmD and Shuntao Cai, PharmD, BCOP
Background
References
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s
In 2014, the PD-1 inhibitors Opdivo (nivolumab) and Keytruda 
(pembrolizumab), became FDA approved for treatment of 
melanoma.1,2 Since then, numerous other agents in the class 
including the PD-1 inhibitor Libtayo (cemiplimab) and the PD-L1 
inhibitors Imfinzi (durvalumab) and Tecentriq (atezolizumab) have 
also become FDA approved for various malignancies. These 
immunotherapy agents work by targeting two proteins called 
programmed death-1 (PD-1) expressed on the surface of immune T 
cells and programmed death ligand-1 (PD-L1) on tumor cells. By 
binding to these sites, PD-1 and PD-L1 inhibitors enhance anti-
cancer immune response thereby serving as a unique treatment 
modality.3
Lee, HT, et al
The Medication Assistance Program (MAP) at Providence Health 
and Services allows patients access to free medications direct from 
the manufacturer when they would otherwise be unable to afford 
them due to lack of insurance coverage and/or off label use. In 
particular, many MAP patients are able to utilize this program to 
receive PD-1 and PD-L1 infusions for advanced  stage cancers 
frequently failing first line regimens. This study will evaluate MAP 
patients on PD-1 and PD-Ll inhibitors for both labeled and 
unlabeled indications to determine safety and efficacy. 
Methods
Objectives
Primary Objective
Determine labeled vs unlabeled indications for which MAP patients 
are receiving PD-1 and PD-L1 inhibitors 
(Labeled = FDA approved indication when patient initiated 
therapy)
(Unlabeled = not FDA approved indication when patient initiated 
therapy)
Secondary Objectives
Determine time to progression of targeted cancer
Determine incidence of adverse drug reactions
Determine financial impact for institution and patient
Hypothesis
The majority of MAP patients will be using PD-1 and PD-L1 
immunotherapy agents for unlabeled  indications.
PD-1 and PD-L1 immunotherapy agents will be effective when 
used for unlabeled indications.
Study Design
• Report of Providence patients on MAP for PD-1 and PD-L1 
therapies will be pulled by the MAP technician in the time frame 
of 10/1/2017 to 8/1/2019. 
• From this report, up to 100 patients will be collected and 
analyzed reverse chronologically for the following: 
• Indication
• Concurrent cancer treatment
• Time period on the medication
• Labeled or unlabeled usage
• Disease progression as measured by mortality or 
metastases on imaging
• Side effect incident, onset and duration  will be 
determined by lab tests and prescription fill history
• Total amount of PD-1 or PD-L1 medication 
• Evaluate data compared to published literature for labeled 
indications. 
Study Setting
Large tertiary medical center
Inclusion Criteria
Any patient getting a PD-1 or PD-L1 inhibitor through MAP
Exclusion Criteria
Patients <18 years old
Pregnant patients
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Results
Results
Indications
• MAP patients on PD-1 and PD-L1 inhibitors are primarily using these 
immunotherapies for unlabeled indications (80%) and the majority (74%) of 
patients are on Opdivo (nivolumab). 
• Sixty six percent of patients are receiving monotherapy, commonly for later 
stage cancers (stage III 18% and stage IV 63%).
• Head and neck (35%), gastroesophageal (17%), and breast cancer (12%) are 
the three highest indications overall. For unlabeled indications, head and 
neck, gastroesophageal and breast cancer were the highest indications. 
Efficacy
• In stage IV head and neck, gastroesophageal, and NSCLC, unlabeled PD-1 
and PD-L1 inhibitors demonstrated a greater ATDP compared to labeled 
indications (8.6 vs 7.3 months, 2.7 vs 1.1 months, and 12.9 vs 0.5 months). 
• Twelve patients were treated with PD-1 and PD-L1 inhibitors for stage II-IV 
breast cancer with some success. ATDP was 8.3 months for stage II and 7.3 
months for stage IV. 
Side effects
• The percentage of patients that experience grade 2 or 3 toxicities requiring 
medication management and delays in immunotherapy treatment are 
comparable between the two groups at 45% for labeled and 46.3% for 
unlabeled indications. 
• The most common ADR noted was hypothyroidism at 25% for labeled 
patients and 20% for unlabeled patients. These patients were usually 
prescribed levothyroxine and then immunotherapy treatment was delayed.
• Other notable ADRs include GI (10% labeled vs 6.3% unlabeled) and 
pneumonitis (15% labeled vs 10% unlabeled).  Diarrhea and GI upset were 
the most commonly noted ADRs per physician notes although it was 
generally not severe enough to warrant delays in immunotherapy treatment. 
Economics
• Some patients initially covered by MAP later transitioned to private 
insurance. This is seen in discrepancy between median amount of medication 
received and median amount of medication received  on MAP.  This 
represents a financial gain, especially with 340B program, in these patients. 
Results
Table 1: Baseline Demographics
Total
Labeled 
(n=20)
Unlabeled 
(n=80) 
Age
<50 10 0 10
50-59 24 5 19
60-69 28 7 21
>70 38 8 30
Gender 
M 65 10 55
F 35 10 25
Cancer Staging
I 14 0 14
II 5 0 5
III 18 2 16
IV 63 18 45
Combination 
therapy
Y 33 5 28
N 66 14 52
Lost to follow up 1 1 0
Research Protocol
Y 18 0 18
N 82 20 62
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Table 3: Outcomes
Labeled (n=20) Unlabeled (n=80) 
ATDP (months) 8.9 4.3
Disease Progression Outcomes
Death (n, %) 5, 25% 18, 22.5%
Metastases (n, %) 4, 20% 22, 27.5%
Average amount of medication received (mg) 2986.75 960
Average amount of medication received as MAP patient (mg) 2612 960
Table 4: Side Effects
Adverse Drug Reactions (ADR)
Labeled 
(n=20)
Unlabeled
(n=80) 
n % n %
1 ADR 6 30% 25 31.3%
2 ADRs 2 10% 9 11.3%
3 ADRs 1 5% 3 3.8%
Total Incidence ADR 9 45% 37 46.3%
Types of ADRs
Infusion 0 0% 0 0.0%
Dermatological 0 0% 2 2.5%
Thyroid 5 25% 16 20.0%
GI 2 10% 5 6.3%
Pneumonitis 3 15% 8 10.0%
Hepatitis 1 5% 8 10.0%
Neurological 1 5% 4 5.0%
Ocular 0 0% 3 3.8%
Myocardial 0 0% 0 0.0%
Other 1 5% 6 7.5%
• Subgroup analysis of unlabeled indications to determine which medications 
have since changed indication from labeled to unlabeled 
• Evaluate side effects compared to literature incident rate and onset of 
common ADRs related to immunotherapy with PD-1 and PD-L1 inhibitors
• Economic analysis in progress to determine medication spend 
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74%
25%
1%
Immunotherapies Used
Opdivo
(nivolumab)
Keytruda
(pembrolizumab)
Imfinzi
(durvalumab)
Head & Neck
Breast Head & Neck Gastroesophageal
O= ovarian cancer, C= colorectal cancer, M = melanoma Opdivo (nivolumab) Keytruda (pembrolizumab) Imfinzi (durvalumab)
OtherGastroesophageal
Table 2: Average Time to Disease Progression (ATDP)
Cancer Types Stage Labeled 
ATDP 
(Months)
Unlabeled 
ATDP 
(Months)
Breast (n=12)
II -- 8.3
III -- N/A
IV -- 7.3
Head and Neck (n=35)
I -- 3.1
II -- N/A
III -- N/A
IV 7.3 8.6
Gastroesophageal (n=17)
I -- 14.8
III -- 8.4
IV 1.1 2.7
Ovarian (n=2)
IV -- 13.5
Colon (n=2)
IV N/A 1.4
Melanoma (n=5)
II -- N/A
III 18.3 N/A
IV -- 35.9
Non-small Cell Lung Cancer (n=9)
III N/A 22.7
IV 0.5 12.9
Prostate (n=5)
IV -- 12.7
Hodgkin Lymphoma (n=1) IV -- N/A
Cutaneous SCC (n=1) IV -- N/A
Pancreatic (n=2) IV -- 10.3
Epitheliod mesothelioma lung (n=1) I -- N/A
Cervical (n=1) III -- 1.9
Endometrial (n=1) IV -- N/A
Procarcinoma sweat gland (n=1) IV -- 4.6
Neuroendocrine (n=1) IV -- 2.0
Merkel cell carcinoma (n=1) IV -- 9.4
Adnexal (n=1) IV -- 3.8
Renal Cell Carcinoma (n=1) IV 5.8 --
Thymus (n=1) IV N/A --
Opdivo( nivolumab) Keytruda (pembrolizumab) Imfinzi (durvalumab)
O MC
Discussion
• High usage of immunotherapy for late stage cancer fits the clinical picture as 
the majority of research for PD-1 and PD-L1 inhibitors is for stage III and 
IV cancers. Early stage cancers are usually treated with first line regimens. 
• High counts of gastroesophageal cancer could be because diagnosis usually 
occurs in patients ~ 65 years old which is the majority of the patient 
population in this study (66% >60 YO).6, 7
• Third line therapy for gastroesophageal cancer is Keytruda so this could 
account for the high amounts for this indication.8 Patient population could 
also be impacted by provider specialties. At this institution, the same 
provider treats gastroesophageal and head and neck cancers. Many of these 
patients are enrolled in the same clinical trial under this physician.  
• PD-1 and PD-L1 for breast cancer is an area that is still being researched so 
it is something to continue tracking to see if the data supports usage. 
• Given that combination therapy was in 25% of labeled patients and 35% of 
unlabeled patients, it is interesting that total incidence of ADR was similar 
between groups. This could be due to variation in supportive medications or 
radiation. 
• MAP represents an opportunity to serve those who may not be able to afford 
high cost medications. 
• MAP data is an opportunity to gain insight to indications that are unlabeled 
because research protocols may not always account for real world scenarios. 
Only 18 of the 80 unlabeled patients were on formal research studies. 
• Without going through MAP, treating each patient will likely result in the 
institution absorbing the drug acquisition cost (median ~$100000-190000).
1,2
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